 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
I have recently taken a small position in AXCA for the following reasons and would welcome a discussion on the merits of the company. 1) AXCA is a pharmaceutical company addressing the gastroenterology market. They are the only Canadian pharmaceutical company with its own US sales and marketing organization. 2) They recently had their shares listed on the NASDAQ and now have them listed there and on the Toronto exchange. 3) Recently released 3rdQ results showed an increase of 214% in revenues and earnings of $0.11 per share compared to $0.03 per share for the same period of 1999.(Please note that this revenue increase was primarily due to an acquisition and the acquisition of the remaining 50% interest that they didn’t already own in another company.) For the first three Q’s, revenues totaled $63.5M and earnings of $0.18 per share. Respectively, this indicates an increase of 320% and 900%. Their current cash and cash equivalents total about $23M. 4)From a recently released report: (a)Gastroenterologist receive more than 26 million visits from patients during the year ending March, 2000. This represents a 6% increase from the prior year. (b)Esophageal disorders were the main reason for these visits. (c)Gastroenterologist wrote prescriptions for $2.7Billion dollars during this period. (d)The top five therapeutic drugs prescribed were for anti-ulcerants(25.9%),GI anti-inflammatory(5.7%), GI stimulants(3.5%), pre-X-ray evacuants(3.4%) and antispasmodic balldonna(2.7%). 5)In March (AXCA) released interim results on the Phase III clinical trails for HELICIDE, a drug for the treatment of Helicobacter pylori(HP). HP is the cause of gastric and duodenal ulcers, affecting at least 10% of the North America population at one point in their lives. HP is found in 50% of the world population, including 25% of the people in North America. Results so far show that HELICIDE is at least as, if not, more effective than the current most widely prescribed therapy for (HP). However, the advantage for HELCIDE is that it overcomes an important compliance problem for patients having to take multiple drugs at different times of the day. HELICIDE is a single dosage pill and is also more cost effective than the current standard treatment. The Phase III results should be released by year-end and if all goes well with the FDA, the drug should be available in early 2002. 6) On August 7,2000, AXCA announced a deal with Diomed for 630 PDT diode lasers and optical delivery fibers for use in photodynamic therapy(PDT). These lasers will be used in conjunction with AXCA’s photosensitizing drug PHOTOFRIN. (PDT) is a novel treatment for certain cancers in which PHOTOFRIN is injected into a patient intravenously and then accumulates in tumor cells. Then after waiting three days, it is activated by the laser light for up to 15 minutes at the tumor site by means of the optical diffuser fiber used in conjunction with an endoscope. This procedures a toxic form of oxygen that subsequently destroys the cancer cells. Currently PHOTOFRIN is being marketed in France, Finland, Germany, Portugal,Sweden,Ireland, Italy, the Netherlands, and the United Kingdom. The treatment is available for esophageal and non-small lung cancers. AXCA recently completed the enrollment of patients for the Phase III trials for the use of PHOTOFRIN in the treatment of dysplasia and metaphasia associated with Barrett’s esophagus, a condition that results from prolonged heartburn and is often a precursor of cancer. Recently Chase/H&Q issued a BUY on the stock. It should be noted that they were involved in the recent $40.1 million public offering here in the U.S. IMO, the current share price being just under $9.00 is a bargain...if all goes well with the potential new drugs and PHOTOFRIN for the treatment of certain cancers | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |